Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 78-85

  Antoniou, G ^a   Kountourakis, P ^a   Papadimitriou, K ^b   Vassiliou, V ^a   Papamichael, D ^a  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adjuvant treatment; Chemotherapy; Pancreatic adenocarcinoma; Radiation therapy; Targeted therapy

Indexed keywords

ALPHA2B INTERFERON; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTHERMIC THERAPY; LONG TERM SURVIVAL; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREDICTIVE VALUE; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REVIEW; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TIME TO TREATMENT;

ADJUVANT TREATMENT; CHEMOTHERAPY; PANCREATIC ADENOCARCINOMA; RADIATION THERAPY; TARGETED THERAPY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84887062417     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.05.008     Document Type: Review

References (98)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA Cancer J Clin 2011, 61(2):133-134.
2. Lau M.K., Davila J.A., Shaib Y.H. Incidence and survival of pancreatic head and body and tail cancers a population-based study in the United States. Pancreas 2010, 39:458-462.
3. Lim J.E., Chien M.W., Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003, 237:74-85.
4. Amptoulach S., Kalaitzakis E., Azam F. Adjuvant chemotherapy should be used as the standard of care for resectable pancreatic cancer. Cancer Therapy 2009, 7:227-233.
5. Chang D.K., Johns A.L., Merrett N.D., Gill A.J., Colvin E.K., Scarlett C.J., et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009, 27(17):2855-2862.
6. Hishinuma S., Ogata Y., Tomikawa M., Ozawa I., Hirabayashi K., Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006, 10(4):511-518.
7. European age-standardised rates calculated by the Statistical Information Team at Cancer Research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. < http://globocan.iarc.fr.
8. Pawlik T.M., Gleisner A.L., Cameron J.L., Winter J.M., Assumpcao L., Lillemoe K.D., et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141(5):610-618.
9. Butturini G., Stocken D.D., Wente M.N., Jeekel H., Klinkenbijl J.H., Bakkevold K.E., et al. Pancreatic cancer meta-analysis group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008, 143(1):75-83.
10. Bilimoria K.Y., Talamonti M.S., Sener S.F., Bilimoria M.M., Stewart A.K., Winchester D.P., et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 2008, 207(4):510-9).
11. Joseph B., Morton J.M., Hernandez-Boussard T., Rubinfeld I., Faraj C., Velanovich V. Relationship between hospital volume, system clinical resources, and mortality in pancreatic resection. J Am Coll Surg 2009, 208(4):520-527.
12. GITSG Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal tumor study group. Cancer 1987, 59(12):2006-2010.
13. Klinkenbijl J.H., Jeekel J., Sahmoud T., van Pel R., Couvreur M.L., Veenhof C.H., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230(6):776.
14. Garofalo M.C. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006, 244(2):332-333.
15. Smeenk H.G., van Eijck C.H.J., Hop W.C. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007, 246(5):734-740.
16. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., et al. European study group for pancreatic cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1200-1210.
17. Choti M.A. Adjuvant therapy for pancreatic cancer-the debate continues. Comment on: a randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350(12):1249-1251.
18. Bakkevold K.E., Arnesjø B., Dahl O., Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993, 29A(5):698-703.
19. Stocken D.D., Büchler M.W., Dervenis C., Bassi C., Jeekel H., Klinkenbijl J.H., et al. Pancreatic cancer meta-analysis group. Meta-Analysis of randomised adjuvant therapy trials for pancreatic cancer". Br J Cancer 2005, 92(8):1372-1381.
20. Van Laethem J.-L., Verslype C., Iovanna J.L., Michl P., Conroy T., Louvet C., et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 2012, 23:570-576.
21. Sinn M., Sinn B.V., Striefler J.K., Stieler J., Niedergethmann M., Gellert K. Long-term survival in patients with pancreatic cancer: Relevant factors in CONKO-001. J Clin Oncol 2012, 30(Suppl.). [Abstract 4020].
22. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297(3):267-277.
23. Neuhaus P., Riess H., Post S., Gellert K., Langrehr J., Ridwelski K., et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 2008, 26:15s. [suppl.; abstr. 4504].
24. Regine W.F., Winter K.A., Abrams R.A., Safran H., Hoffman J.P., Konski A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299(9):1019-1026.
25. Regine W.F., Winter K.A., Abrams R., Safran H., Hoffman J.P., Konski A., et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011, 18(5):1319-1326.
26. Berger A.C., Garcia M., Hoffman J.P., Regine W.F., Abrams R.A., Safran H., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008, 26(36):5918-5922.
27. Ueno H., Kosuge T., Matsuyama Y., Yamamoto J., Nakao A., Egawa S., et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer 2009, 101(6):908-911.
28. Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., et al. For the European study group for pancreatic cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304(10):1073-1081.
29. Chang D.K., Jamieson N.B., Johns A.L., Scarlett C.J., Pajic M., Chou A., et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013, 31(10):1348-1356.
30. Schmidt J., Abel U., Debus J., Harig S., Hoffmann K., Herrmann T., et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012, 30:4077-4083.
31. Uesaka K., Fukutomi A., Boku N., Kanemoto H., et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 2012, 30(Suppl. 34). [abstr. 145].
32. Takada T., Amano H., Yasuda H., Nimura Y., Matsushiro T., Kato H., et al. Study group of surgical adjuvant therapy for carcinomas of the pancreas and biliary tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95(8):1685-1695.
33. Kosuge T., Kiuchi T., Mukai K., Kakizoe T. Japanese study group of adjuvant therapy for pancreatic cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006, 36(3):159-165.
34. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schönekäs H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24:3946-3952.
35. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Cartenì G., Massidda B., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010, 28:1645-1651.
36. Wang X., Ni Q., Jin M., Li Z., Wu Y., Zhao Y., et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhongliu Zazhi (Chinese Journal of Oncology) 2002, 24:404-407.
37. Picozzi V.J., Abrams R.A., Decker P.A., Traverso W., O'Reilly E.M., Greeno E., et al. American college of surgeons oncology group. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011, 22(2):348.
38. Cartwright T.H., Cohn A., Varkey J.A., Chen Y.M., Szatrowski T.P., Cox J.V., et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160-164.
39. Yang X., Wu C.S.U., Hwang J.J., Weinberg B., Pishvaian M.J., He A.R., et al. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy. J Clin Oncol 2012, 30(Suppl. 4). [abstr. 333].
40. Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009, 27:5513-5518.
41. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schüller J., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multi- center, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25:2212-2217.
42. UK Clinical Research Network: Portfolio Database. ESPAC-4 Trial. < http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=4307.
43. Reni M., Balzano G., Aprile G., Cereda S., Passoni P., Zerbi A., et al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol 2012, 19(7):2256-2263.
44. Herman J.M., Swartz M.J., Hsu C.C., Winter J., Pawlik T.M., Sugar E., et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008, 26(21):3503-3510.
45. Corsini M.M., Miller R.C., Haddock M.G., Donohue J.H., Farnell M.B., Nagorney D.M., et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008, 26(21):3511-3516.
46. Yip D., Karapetis C., Strickland A., Steer C.B., Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006, 3:CD002093.
47. Sultana A., Tudur Smith C., Cunningham D., Starling N., Neoptolemos J.P., Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008, 99:6-13.
48. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
49. Clinical Trials Gov. A service of the US National Institutes of Health < (Last updated 06.08.12). http://clinicaltrials.gov/ct2/show/NCT01660711.
50. Clinical Trials Gov. A service of the US National Institutes of Health < (Last updated 18.03.13). http://clinicaltrials.gov/ct2/show/NCT01595321.
51. Stathopoulos G.P., Syrigos K., Aravantinos G., Polyzos A., Papakotoulas P., Fountzilas G., et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monother-apy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006, 95:587-592.
52. Zaniboni A., Aitini E., Barni S., Ferrari D., Cascinu S., Catalano V., et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012, 69(6):1641-1645.
53. De Jesus-Acosta A., Oliver G.R., Blackford A., Kinsman K., Flores E.I., Wilfong L.S., et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012, 69(2):415-424.
54. Lutz M.P., Van Cutsem E., Wagener T., Van Laethem J.L., Vanhoefer U., Wils J.A., et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European organisation for research and treatment of cancer gastrointestinal group. J Clin Oncol 2005, 23:9250-9256.
55. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
56. Von Hoff D., Ervin T.J., Arena F.P., Chiorean E.G., Infante J.R., Moore M.J., et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2012, 30(Suppl. 34). [Abstract LBA148].
57. Kullmann F., Hollerbach S., Dollinger M.M., Harder J., Fuchs M., Messmann H., et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 2009, 100:1032-1036.
58. Philip P.A. Improving treatment of pancreatic cancer. Lancet Oncol 2008, 9(1):7-8.
59. Pipas J.M., Zaki B.I., McGowan M.M., Tsapakos M.J., Ripple G.H., Suriawinata A.A., et al. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol 2012, 23(11):2820-2827.
60. Philip P.A., Benedetti J., Corless C.L., Wong R., O'Reilly E.M., Flynn P.J., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial s0205. J Clin Oncol 2010, 28:3605-3610.
61. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2007, 25(15):1960-1966.
62. Heinemann V., Vehling-Kaiser U., Waldschmidt D., Kettner E., Märten A., Winkelmann C., et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013, 62(5):751-759.
63. Fountzilas G., Bobos M., Kalogera-Fountzila A., Xiros N., Murray S., Linardou H., et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II study of the hellenic cooperative oncology group with biomarker evaluation. Cancer Invest 2008 Oct, 26(8):784-793.
64. Larbouret C., Gaborit N., Chardès T., Coelho M., Campigna E., Bascoul-Mollevi C., et al. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/ erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption dual EGFR/HER2 targeting in pacreatic cancer. Neoplasia 2012, 14(2):121-130.
65. Wu Z., Marshall J., JJ Hwang, MJ Pishvaian, A Wellstein, LM Weiner, et al. A phase II study of lapatinib and capecitabine in second-line treatment of metastatic pancreatic cancer. J Clin Oncol 2012, 30(Suppl.). [Abstract e14569].
66. Safran H., Iannitti D., Ramanathan R., Schwartz J.D., Steinhoff M., Nauman C., et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004, 22:706-712.
67. Borad M.J., Sigal D., Uronis H., Stephenson J., Bahary N., Rarick M.U., et al. Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. The TH-CR-404 Study. J Clin Oncol 2011, 29(Suppl.). [Abstract TPS176].
68. Clinical Trials Gov. A service of the US National Institutes of Health. <(Last updated 18.12.12). http://clinicaltrials.gov/ct2/show/NCT01746979.
69. Stephenson J., Richards D.A., Wolpin B.M., Becerra C., Hamm J.T., Messersmith W.A. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2011, 29(Suppl.).
70. Catenacci D.V.T., Bahary N., Edelman M.J., Nattam S.R., de Wilton Marsh R., Kaubisch A., et al. A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study. J Clin Oncol 2012, 30(Suppl.). [Abstract 4022].
71. Arya G., Vandana M., Acharya S., Sahoo S.K. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine. 2011, 7(6):859-870.
72. Ko A.H., Youssoufian H., Gurtler J., Dicke K., Kayaleh O., Lenz H.J., et al. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012, 30(4):1597-1606.
73. Kindler H.L., Ioka T., Richel D.J., Bennouna J., Létourneau R., Okusaka T., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase III study. Lancet Oncol 2011, 12:256-262.
74. Keating J.J., Johnson P.J., Cochrane A.M., Gazzard B.G., Krasner N., Smith P.M., et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989, 60:789-792.
75. Fazeny B., Baur M., Prohaska M., Hudec M., Kremnitzer M., Meryn S., et al. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer-results of a pilot study and review of the literature. J Cancer Res Clin Oncol 1997, 123:45-52.
76. Clinical Trials Gov. A service of the US National Institutes of Health < (Last updated 18.12.12). http://clinicaltrials.gov/ct2/show/NCT00389610.
77. Hardacre J.M., Mulcahy M.F., Small W., Talamonti M.S., Obel J.C., Rocha Lima C.M.S. Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. J Clin Oncol 2012, 30(Suppl.). [Abstract 4049].
78. Clinical Trials Gov. A service of the US National Institutes of Health < (Last updated 21.05.13). http://clinicaltrials.gov/ct2/show/NCT01072981.
79. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321(5897):1801-1806.
80. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1):187-195.
81. Maréchal R., Van Laethem J.L. Towards a tailored therapy in pancreatic cancer. Acta Gastroenterol Belg 2013 Mar, 76(1):49-56.
82. Maithel S.K., Coban I., Kneuertz P.J., Kooby D.A., El-Rayes B.F., Kauh J.S., et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol 2011, 18(9):2699-2705.
83. Bachet J.B., Maréchal R., Demetter P., Bonnetain F., Couvelard A., Svrcek M., et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinomas. Ann Oncol 2012, 23(9):2327-2335.
84. Fisher S.B., Patel S.H., Bagci P., Kooby D.A., El-Rayes B.F., Staley C.A., et al. An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment. J Clin Oncol 2012, 30(Suppl. 4). [abstr. 206].
85. Iacobuzio-Donahue C.A., Fu B., Yachida S., Luo M., Abe H., Henderson C.M., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27(11):1806.
86. Wolpin B.M., O'Reilly E.M., Ko Y., Blaszkowsky L.S., Rarick M.U., Rocha Lima C.M.S., et al. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 2011, 29(Suppl.):4031.
87. Mahon P.C., Baril P., Bhakta V., Chelala C., Caulee K., Harada T., et al. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007, 67:6786-6795.
88. Biankin A.V., Kench J.G., Colvin E.K., Segara D., Scarlett C.J., Nguyen N.Q., et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009, 137:558-568. [568 e551-511].
89. Tempero M.A., Moughan J., Kim G.E., Kakar S., Hyun T.S., Regine W., et al. S100A4 as a biomarker of resistance to gemcitabine: A secondary analysis of RTOG 9704. J Clin Oncol 2012, 30(Suppl. 4). [abstr. 165].
90. Olive K.P., Davidson C.J., Jacobetz M.A., Honess D., McIntyre D., Madhu B., et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
91. Saif M.W. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the 2011 ASCO Gastrointestinal Cancers Symposium. J Pancreas (Online) 2011, 12(2):106-109.
92. Evans D.B., Varadhachary G.R., Crane C.H., Sun C.C., Lee J.E., Pisters P.W., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3496-3502.
93. Varadhachary G.R., Wolff R.A., Crane C.H., Sun C.C., Lee J.E., Pisters P.W., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26(21):3487-3495.
94. Palmer D.H., Stocken D.D., Hewitt H., Markham C.E., Hassan A.B., Johnson P.J., et al. A randomized phase II trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007, 14(7):2088.
95. Cioffi M., Heeschen C. Immuno-targeting of pancreatic cancer stem cells: a new therapeutic strategy against a devastating disease?. OncoImmunology 2012, 1:560-562.
96. Seton-Rogers S. Metastasis navigating uncharted territory. Nat Rev Cancer 2012, 12(3):151.
97. Clinical Trials Gov. A service of the US National Institutes of Health < http://clinicaltrials.gov/ct2/show/NCT00004087?term=pancreas+stem+cells&rank=2.
98. Hidalgo M., Von Hoff D.D. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2012, 18:4249-4256.